Table 4.

The side-effect of patients with aPAP during the GM-CSF treatment and follow up period

	Treatment periods			Follow up periods
	No treatment group (n = 17)	Treatment group (n = 19)	P value	No treatment group (n = 12)	Treatment group (n = 16)	P value
Leukocytosis	1/17 (5.9%)	1/19 (5.3%)	1.0a	1/12 (8.3%)	0/16 (0)	0.429a
Increase in aminotransferases	4/17 (23.5%)	11/19 (57.9%)	0.037	6/12 (50.0%)	4/16 (25.0%)	0.333b
Increase in bilirubin	6/17 (35.3%)	2/19 (10.5%)	0.167b	4/12 (33.3%)	0/16 (0)	0.051b

^a: Fisher X² test; ^b: continuous correction X² test